# Morgan Stanley Direct Lending Fund: overview MSDL · NYSE · CIK 1782524 · [Other](/sectors/other.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/msdl.md) · [Financials](/companies/msdl/financials.md) · [Filings](/companies/msdl/filings.md) · [Insiders](/companies/msdl/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [0.60](/filings/0001193125-25-269438.md) | not reported | [0.34](/filings/0001193125-26-211906.md) | [0.41](/filings/0001193125-26-337915.md) | [0.32](/filings/0001193125-25-269438.md) | not reported | [(0.05)](/filings/0001193125-26-211906.md) | [0.09](/filings/0001193125-26-337915.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL not reported. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2021-12-31) | FY (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [2.67](/filings/0001782524-24-000009.md) | [0.79](/filings/0001782524-25-000009.md) | [3.11](/filings/0001193125-26-076632.md) | [2.43](/filings/0001193125-26-076632.md) | [1.40](/filings/0001193125-26-076632.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL not reported. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/msdl/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $237.7m | 15,723,274 | | Reduced −151,088 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $39.0m | 2,581,090 | | Added +984,494 | | [VAN ECK ASSOCIATES CORP](/funds/869178.md) | 2026-06-30 | $30.5m | 2,014,119 | | Added +580,142 | | [Generali Asset Management SPA SGR](/funds/2046751.md) | 2026-06-30 | $27.7m | 1,829,964 | | Unchanged | | [Lunate Capital Ltd](/funds/2056786.md) | 2026-06-30 | $16.7m | 1,103,814 | | New +1,103,814 | | [Russell Investments Group, Ltd.](/funds/1692234.md) | 2026-06-30 | $16.1m | 1,061,802 | | Added +339,853 | | [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $13.5m | 893,188 | | Added +3,839 | | [Muzinich & Co., Inc.](/funds/1618824.md) | 2026-06-30 | $12.7m | 838,899 | | Added +71,097 | | [ARES MANAGEMENT LLC](/funds/1259313.md) | 2026-06-30 | $11.7m | 775,128 | | Added +363,128 | | [Ensign Peak Advisors, Inc](/funds/1454984.md) | 2026-06-30 | $11.3m | 748,000 | | New +748,000 | ## Recent filings [All 407 filings](/companies/msdl/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-05 | 20:22 ET | [8-K](/filings/0001193125-26-414170.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-414170 | | 2026-09-29 | 21:01 ET | [8-K](/filings/0001193125-26-407757.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-407757 | | 2026-08-06 | 20:53 ET | [8-K](/filings/0001193125-26-338351.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-338351 | | 2026-08-06 | 20:04 ET | [10-Q](/filings/0001193125-26-337915.md) | Quarterly report, period 2026-06-30 | 0001193125-26-337915 | | 2026-07-09 | 20:30 ET | [8-K](/filings/0001193125-26-299743.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-26-299743 | | 2026-07-06 | 20:11 ET | [8-K](/filings/0001193125-26-296188.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-296188 | | 2026-07-01 | 21:01 ET | [8-K](/filings/0001193125-26-292783.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-292783 | | 2026-06-02 | 20:24 ET | [8-K](/filings/0001193125-26-253571.md) | 5.07 Shareholder vote results | 0001193125-26-253571 | | 2026-05-29 | 20:03 ET | [8-K](/filings/0001193125-26-248218.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-248218 | | 2026-05-07 | 20:21 ET | [8-K](/filings/0001193125-26-212041.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-212041 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-076632.md), filed Feb 26, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1782524 - Tickers: MSDL - Exchange: NYSE - SIC code: not reported - State of incorporation: DE - Filer category: Large accelerated filer Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.